SOURCE: Leerink Swann & Company

September 29, 2005 08:34 ET

Leerink Swann & Company Initiates Coverage of Forest Laboratories, Inc. (NYSE: FRX)

BOSTON, MA -- (MARKET WIRE) -- September 29, 2005 -- This morning, Senior Specialty Pharmaceuticals Analyst, Gary Nachman, initiated coverage of Forest Laboratories, Inc. (NYSE: FRX) with a Market Perform rating. He believes the risk/reward profile does not justify owning the stock at these levels. Lexapro accounts for roughly two-thirds of sales and has a number of clouds hanging over it, most notably generic litigation.

About Forest Laboratories, Inc.

Forest Laboratories, Inc. (NYSE: FRX) identifies, develops and delivers pharmaceutical products. It has well-established franchises in therapeutic areas of the central nervous, cardiovascular and respiratory systems. The company is headquartered in New York City.

About Leerink Swann & Company

Leerink Swann & Company is an investment banking firm that provides healthcare equity research, corporate finance, and asset management services for institutional and high-net-worth clients. Leerink Swann & Company was voted the Best Firm in Biotechnology, Medical Supplies and Devices, Pharmaceuticals/Major and Pharmaceuticals/Specialty in the December 2004 Institutional Investor poll ranking the best boutique and regional firms by sector. Through its consulting affiliate, MEDACorp, Leerink Swann & Company provides biomedical-consulting services to Life Sciences companies and to the institutional investment community. MEDACorp includes thousands of biomedical professionals and practicing physicians. Leerink Swann & Company is a member NASD/SIPC.

Contact Information

  • Contact:
    John I. Fitzgerald
    Leerink Swann & Company
    (617) 918-4564